相关实验视频
Updated: May 16, 2025
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
在临床前阶段的异质沉积模式与特定领域的认知缺陷有关
Seyed Hani Hojjati1, Gloria C Chiang1, Tracy A Butler1
1Department of Radiology, Brain Health Imaging Institute, Weill Cornell Medicine, New York, New York, USA.
概括
在认知健康的成年人中发现了七种不同的tau沉积模式,将中间叶和新皮质模式与特定的认知缺陷和生物标志物联系起来. 这推动了早期阿尔茨海默病 (AD) 检测和干预策略的发展.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物标志物 生物标志物
背景情况:
- 陶沉积的空间异质性与阿尔茨海默病 (AD) 的临床变异相关.
- 早期检测临床前的型是具有挑战性的.
- 第二代标记剂为临床前阿尔茨海默病研究提供了新的机会.
研究的目的:
- 用先进的成像技术识别和描述认知健康的成年人中的沉积模式.
- 调查临床前型和人口,遗传和流体生物标志物之间的关联.
- 探索临床前tau模式与认知功能之间的关系.
主要方法:
- 使用18F-MK6240标记器进行了独立组件分析 (ICA) 和陶正子发射断层扫描 (PET) 成像.
- 分析了来自590名认知健康成年人的数据 (平均年龄66.58±5.13岁,340名女性).
- 与年龄相关联的确定的tau模式,粉样β (Aβ) 负担,阿波利波蛋白E (APOE) 基因型,血总tau和认知表现.
主要成果:
- 在临床前AD中确定了七种不同的tau沉积模式.
- 与年龄,Aβ负担,APOE基因型和血总量相关的中叶 (MTL) 模式.
- 双边的杏仁体-海马体沉积会对记忆产生负面影响.
- 与语言和推理缺陷相关的不对称的新皮层tau模式.
结论:
- 临床前阿尔茨海默病的沉积模式是异质的,并与特定的生物标志物和认知特征相关.
- 这些发现为早期AD检测和个性化干预策略提供了关键的见解.
- 这项研究强调了TAU PET成像用于理解临床前AD异质性的潜力.
相关概念视频
01:26Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350
01:30Dementia
76
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
76
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133